CTI Life Sciences Fund
VC Fund
Montréal, Canada
CTI Life Sciences Fund is a VC fund in Montréal focused on Biotechnology and Health Care. CTI Life Sciences, a Canadian venture firm makes venture capital investments in high quality emerging life sciences companies at the pre-clinical and clinical development stage in Canada and in the U.S. CTI Life Sciences currently manage $345 million of assets.
- Total investments:
- 37
- Last investment:
- Lead investor:
- 24%
- Fund size:
- $100M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries CTI Life Sciences Fund invests in
Stages CTI Life Sciences Fund invests in
Countries CTI Life Sciences Fund invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $2M–$31M
- Series A
- $7.2M–$62M
- Series B
- $10M–$100M
Investment Focus
Industry
- Biotechnology 21 (57%)
- Health Care 12 (32%)
- Therapeutics 10 (27%)
- Pharmaceutical 8 (22%)
- Medical 5 (14%)
Stage
- Series A 8 (22%)
- Series B 8 (22%)
- Seed 3 (8%)
- Series C 3 (8%)
- Venture - Series Unknown 3 (8%)
Country
- Canada 14 (38%)
- United States 7 (19%)
- Spain 1 (3%)
- France 1 (3%)
- United Kingdom 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Youssef Bennani
Managing Partner
|
Managing Partner | Total investments: 3 | Find email | |
Jean-Francois Leprince
Managing Partner
|
Managing Partner | Total investments: 0 | Find email | |
Ken Pastor
General Partner
|
General Partner | Total investments: 0 | Find email | |
Shermaine Tilley
Managing Partner
|
Managing Partner | Total investments: 9 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identifyorthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs. | $23.5M / Series B / Feb 09, 2026 | ||
| Find therapeutics provides biotechnology research services. They also provide CTI life sciences, frontiers of therapy, treat inflammatory autoimmune diseases, domain therapeutics, and GPCR technology services. | $7.2M / Series A / Jan 09, 2026 | ||
| Aeovian Pharmaceuticals develops and investigates targeted small molecule therapeutics aimed at restoring cellular metabolic quality control to address dysregulated growth and signaling linked to certain rare genetic and age-related conditions. The company’s pipeline centers on compounds that selectively modulate specific biological pathways,including inhibitors designed to influence disease processes associated with neurological dysfunction. Its lead development candidate is a central nervous system-penetrant selective inhibitor being evaluated in clinical trials for refractory seizures related to a genetic disorder, and additional compounds are in earlier stages of investigation for other disease areas. Aeovian Pharmaceuticals also maintains a portfolio of proprietary molecules that engage defined molecular targets to explore potential treatments beyond its program. | $55M / Series B / Dec 16, 2025 | ||
| Oligon company provides emerging biotechnology services developing a novel class of multimodal RNA therapeutics. They provide RNA oligonucleotide consultants, research associates, and research scientists. Their contact is done through phone and email. | $14M / Sep 23, 2025 | ||
| Thryv Therapeutics is a genetic disorder that causes a prolongation between the beginning of the QRS complex and the end of the T waveQ and T waves on the EKG, indicating a prolongation of ventricular repolarization and the action potential duration. The lengthening of this complex is associated with unexpected and life-threatening ventriculararrhythmias. Click below to learn more about our programs. | Sep 17, 2025 | ||
| Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs.Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The companydevelops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures.Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization. | Venture - Series Unknown / Sep 17, 2025 | ||
| Glycomine is early-stage biotech working on replacement therapies for rare diseases. There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA-approved treatment. Glycomine develops therapeutics for diseases that have no treatment options. | $115M / Series C / Apr 16, 2025 | ||
| Epitopea is a transatlantic biotechnology company developing transformational immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. Cryptigen™ TSAs are discovered by a proprietary approach deploying immunopetidomics, mass spectrometry, genomics, andbioinformatics, which allows the identification of conserved, aberrantly-expressed, tumour-specific antigens, hidden in cancer's 'junk' DNA. These hidden Cryptigen™ TSAs have been identified by research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal. | $31M / Seed / Oct 24, 2024 | ||
| Find therapeutics provides biotechnology research services. They also provide CTI life sciences, frontiers of therapy, treat inflammatory autoimmune diseases, domain therapeutics, and GPCR technology services. | $8.1M / Convertible Note / Sep 16, 2024 | ||
| Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs.Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The companydevelops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures.Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization. | $7.7M / Venture - Series Unknown / Mar 11, 2024 | ||
| See all 37 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does CTI Life Sciences Fund invest in?
CTI Life Sciences Fund invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 37 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does CTI Life Sciences Fund invest in?
CTI Life Sciences Fund typically joins rounds of $2M–$31M at Seed, $7.2M–$62M at Series A and $10M–$100M at Series B. These are whole funding-round sizes, not CTI Life Sciences Fund's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds CTI Life Sciences Fund took part in.
How do I contact CTI Life Sciences Fund?
Public channels for CTI Life Sciences Fund include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at CTI Life Sciences Fund?
The team at CTI Life Sciences Fund includes Youssef Bennani (Managing Partner), Jean-Francois Leprince (Managing Partner) and Ken Pastor (General Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
